Acute Asthma Exacerbation
Patient presents with acute worsening of asthma symptoms (wheeze, SOB, cough, chest tightness)
All Pathways
Pulmonary MedicineEmergency
Acute Asthma Exacerbation Management (GINA 2025)
Acute Asthma Exacerbation Management (GINA 2025): Acute Asthma Exacerbation → Assess Severity → ⚠️ Life-Threatening → ICU/HDU Admission.
Pathway Overview
12 steps
Algorithm Steps
12 total
01Start 02Decision Assess Severity
Evaluate talking, alertness, respiratory rate, accessory muscle use, pulse, SpO2, PEF
- Mild-Moderate: Talks in phrases, prefers sitting, RR increased, no accessory muscles, HR 100-120, SpO2 90-95%
- Severe: Talks in words, sits hunched forward, RR >30, accessory muscles, HR >120, SpO2 <90%
- Life-threatening: Drowsy/confused, silent chest, bradycardia, SpO2 <90%
03Warning ⚠️ Life-Threatening
Immediate ICU/resuscitation - prepare for intubation
- Silent chest, cyanosis, poor respiratory effort
- Bradycardia, hypotension, exhaustion/confusion
- PEF <25% predicted or unmeasurable
- Call for senior/ICU support immediately
04Outcome ICU/HDU Admission
For severe/life-threatening asthma
- Requiring ventilatory support
- Deteriorating PEF/symptoms despite treatment
- Hypercapnia or severe hypoxia
- Exhaustion, drowsiness, confusion
05Action Initial Treatment (First Hour)
Start SABA + controlled oxygen + consider corticosteroids
- SABA: Salbutamol 4-10 puffs via pMDI+spacer every 20 min x3, OR 2.5-5mg nebulized
- Oxygen: Target SpO2 93-95% (94-98% in children)
- Corticosteroids: Prednisolone 40-50mg PO or Hydrocortisone 100mg IV
- If severe: Add ipratropium 500mcg nebulized every 20 min x3
06Decision Reassess at 1 Hour
Evaluate response to treatment
- Good response: Symptoms improved, PEF >60-80% predicted, SpO2 >94%
- Incomplete response: Some improvement but not resolved
- Poor response: No improvement or worsening
07Action Good Response
Continue monitoring, prepare for discharge
- Observe for 1 hour after last nebulizer
- Continue oral prednisolone 40-50mg daily x 5-7 days
- Review inhaler technique
- Provide written asthma action plan
08Outcome Discharge with Action Plan
Criteria met for safe discharge
- PEF >75% predicted or personal best
- SpO2 >94% on room air
- Adequate inhaler technique demonstrated
- Oral corticosteroids for 5-7 days
- Follow-up appointment within 2-7 days
09Action Incomplete Response
Intensify treatment
- Continue SABA every 60 min
- Add ipratropium if not already given
- Consider IV magnesium sulfate 2g over 20 min (if severe)
- Continue monitoring, reassess frequently
10Action IV Magnesium Sulfate
For severe exacerbation not responding to initial treatment
- Dose: 1.2-2g IV over 20 minutes
- Single dose only
- Monitor BP during infusion
- Not routinely recommended for mild-moderate
11Outcome Admit to Hospital
For ongoing treatment and monitoring
- SpO2 <92% on room air
- PEF <50% predicted after treatment
- Unable to maintain improvement
- High-risk features present
- Social/psychological factors
- Path rejoins step 04Shared downstream outcome
- Path rejoins step 11Shared downstream outcome
12Action Poor Response/Worsening
Escalate care
- IV magnesium sulfate 2g over 20 min if not given
- Consider IV salbutamol 250mcg slowly
- Urgent ICU referral if deteriorating
- Prepare for possible intubation
- Path rejoins step 10Shared downstream outcome
- Path rejoins step 04Shared downstream outcome
Guideline Source
Global Initiative for Asthma (GINA) 2025 Strategy Report
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address life-threatening asthma requiring immediate intubation
- Pediatric dosing differs - refer to pediatric guidelines for children <6 years
- Does not cover asthma in pregnancy (special considerations apply)
- Drug dosing may need adjustment for severe renal/hepatic impairment
Contraindicated Populations
neonates
Applicable Regions
Global
Global: GINA guidelines are internationally recognized and adaptable to local resources
Version 1Next review: 2027-05-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Pulmonary Embolism Severity Index (PESI)
30-day mortality risk stratification for acute pulmonary embolism
Open page
Compare
AttendMe.ai vs DynaMed
See how this pathway workflow compares against DynaMed.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Acute Asthma Exacerbation Management (GINA 2025)?
The Acute Asthma Exacerbation Management (GINA 2025) is a emergency clinical algorithm for Pulmonary Medicine. It provides a structured decision tree to guide clinical decision-making, based on Global Initiative for Asthma (GINA) 2025 Strategy Report.
What guideline is the Acute Asthma Exacerbation Management (GINA 2025) based on?
This algorithm is based on Global Initiative for Asthma (GINA) 2025 Strategy Report (DOI: ginasthma.org/2025-gina-strategy-report).
What are the limitations of the Acute Asthma Exacerbation Management (GINA 2025)?
Known limitations include: Does not address life-threatening asthma requiring immediate intubation; Pediatric dosing differs - refer to pediatric guidelines for children <6 years; Does not cover asthma in pregnancy (special considerations apply); Drug dosing may need adjustment for severe renal/hepatic impairment. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Acute Asthma Exacerbation Management (GINA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free